Evidence map›Paper›PMID 38108067›Full record

ReviewFrontiers in pharmacology2023

Tanshinone IIA: a Chinese herbal ingredient for the treatment of atherosclerosis.

Chunkun Yang, Yanguang Mu, Shuanghong Li, Yang Zhang, Xiaoyuan Liu, Jun Li

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Cardiovascular Benefits ofFood science & nutrition · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Tanshinone IIA Restrains Hepatocellular Carcinoma Progression by Regulating METTL3-Mediated m6A Modification of TRIB3 mRNA.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Chunkun Yang *Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Yanguang Mu *Weifang People's Hospital, Weifang, China.
Shuanghong LiWeifang Hospital of Traditional Chinese Medicine, Weifang, China.
Yang ZhangWeifang People's Hospital, Weifang, China.
Xiaoyuan LiuWeifang Hospital of Traditional Chinese Medicine, Weifang, China.
Jun LiGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Weifang Chinese Medicine Hospital · CNWeifang People's Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNGuang’anmen Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tanshinone IIA (Tan IIA) is a fat-soluble compound extracted from

Indexed as

adhesionadverse drug reactionsatherosclerosisplaquestanshinone IIAvascular endothelial cellsvascular smooth muscle cells

Identifiers

PMID38108067
PMCPMC10722201
OpenAlexW4389236325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.